

Katsuyuki Kiura

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6784961/publications.pdf>

Version: 2024-02-01

254
papers

6,852
citations

126907

33
h-index

71685

76
g-index

261
all docs

261
docs citations

261
times ranked

7286
citing authors

#	ARTICLE	IF	CITATIONS
1	CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1&2 study. <i>Lancet Oncology</i> , The, 2013, 14, 590-598.	10.7	555
2	Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 874-886.	10.7	453
3	Presence of Epidermal Growth Factor Receptor Gene T790M Mutation as a Minor Clone in Non"Small Cell Lung Cancer. <i>Cancer Research</i> , 2006, 66, 7854-7858.	0.9	422
4	Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor <i>BRAF</i> gene mutations but lack mutations in <i>KRAS</i> , <i>NRAS</i> , or <i>MEK1</i> . <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, E2127-33.	7.1	410
5	Meta-Analysis of Randomized Clinical Trials Comparing Cisplatin to Carboplatin in Patients With Advanced Non"Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2004, 22, 3852-3859.	1.6	373
6	The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers. <i>Clinical Cancer Research</i> , 2005, 11, 1167-73.	7.0	344
7	Phase III Trial Comparing Docetaxel and Cisplatin Combination Chemotherapy With Mitomycin, Vindesine, and Cisplatin Combination Chemotherapy With Concurrent Thoracic Radiotherapy in Locally Advanced Non"Small-Cell Lung Cancer: OLCSG 0007. <i>Journal of Clinical Oncology</i> , 2010, 28, 3299-3306.	1.6	225
8	Effect of gefitinib (Iressa TM , ZD1839) on brain metastases in patients with advanced non-small-cell lung cancer. <i>Lung Cancer</i> , 2004, 46, 255-261.	2.0	175
9	Emergence of Epidermal Growth Factor Receptor T790M Mutation during Chronic Exposure to Gefitinib in a Non"Small Cell Lung Cancer Cell Line. <i>Cancer Research</i> , 2007, 67, 7807-7814.	0.9	170
10	The Role of STAT3 in Non-Small Cell Lung Cancer. <i>Cancers</i> , 2014, 6, 708-722.	3.7	154
11	Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2016, 17, 1147-1157.	10.7	122
12	A Phase II Study of Trastuzumab Emtansine in HER2-Positive Non"Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018, 13, 273-279.	1.1	119
13	Re-biopsy status among non-small cell lung cancer patients in Japan: A retrospective study. <i>Lung Cancer</i> , 2016, 101, 1-8.	2.0	118
14	Non"Small Cell Lung Cancer Cells Acquire Resistance to the ALK Inhibitor Alectinib by Activating Alternative Receptor Tyrosine Kinases. <i>Cancer Research</i> , 2016, 76, 1506-1516.	0.9	115
15	Afatinib versus cisplatin plus pemetrexed in Japanese patients with advanced non"small cell lung cancer harboring activating <i>EGFR</i> mutations: Subgroup analysis of LUX–Lung 3. <i>Cancer Science</i> , 2015, 106, 1202-1211.	3.9	99
16	A Randomized, Double-Blind, Phase IIa Dose-Finding Study of Vandetanib (ZD6474) in Japanese Patients With Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2008, 3, 386-393.	1.1	88
17	The Impact of Sex and Smoking Status on the Mutational Spectrum of Epidermal Growth Factor Receptor Gene in Non"small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2007, 13, 5763-5768.	7.0	81
18	Comparison of the Incidence and Pattern of Interstitial Lung Disease During Erlotinib and Gefitinib Treatment in Japanese Patients with Non-small Cell Lung Cancer: The Okayama Lung Cancer Study Group Experience. <i>Journal of Thoracic Oncology</i> , 2010, 5, 179-184.	1.1	69

#	ARTICLE	IF	CITATIONS
19	The impact of body mass index on the efficacy of anti-PD-1/PD-L1 antibodies in patients with non-small cell lung cancer. <i>Lung Cancer</i> , 2020, 139, 140-145.	2.0	68
20	Effects of Vandetanib on Lung Adenocarcinoma Cells Harboring Epidermal Growth Factor Receptor T790M Mutation <i>in vivo</i> . <i>Cancer Research</i> , 2009, 69, 5091-5098.	0.9	65
21	Three-Year Follow-Up of an Alectinib Phase I/II Study in ALK-Positive Non-Small-Cell Lung Cancer: AF-001JP. <i>Journal of Clinical Oncology</i> , 2017, 35, 1515-1521.	1.6	63
22	Afatinib Prolongs Survival Compared with Gefitinib in an Epidermal Growth Factor Receptor-Driven Lung Cancer Model. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 589-597.	4.1	62
23	A single-arm confirmatory study of amrubicin therapy in patients with refractory small-cell lung cancer: Japan Clinical Oncology Group Study (JCOG0901). <i>Lung Cancer</i> , 2014, 84, 67-72.	2.0	62
24	Mechanisms of Acquired Resistance to ALK Inhibitors and the Rationale for Treating ALK-positive Lung Cancer. <i>Cancers</i> , 2015, 7, 763-783.	3.7	59
25	Dramatic effect of ZD1839 (Iressa™) in a patient with advanced non-small-cell lung cancer and poor performance status. <i>Lung Cancer</i> , 2003, 40, 73-76.	2.0	54
26	Activation of downstream epidermal growth factor receptor (EGFR) signaling provides gefitinib-resistance in cells carrying EGFR mutation. <i>Cancer Science</i> , 2007, 98, 357-363.	3.9	48
27	Reappraisal of Short-term Low-volume Hydration in Cisplatin-based Chemotherapy: Results of a Prospective Feasibility Study in Advanced Lung Cancer in the Okayama Lung Cancer Study Group Trial 1002. <i>Japanese Journal of Clinical Oncology</i> , 2013, 43, 1115-1123.	1.3	48
28	Src mediates ERK reactivation in gefitinib resistance in non-small cell lung cancer. <i>Experimental Cell Research</i> , 2014, 322, 168-177.	2.6	43
29	The effect and safety of immune checkpoint inhibitor rechallenge in non-small cell lung cancer. <i>Japanese Journal of Clinical Oncology</i> , 2019, 49, 762-765.	1.3	43
30	Epidermal Growth Factor Receptor Mutation Status and Adjuvant Chemotherapy With Uracil-Tegafur for Adenocarcinoma of the Lung. <i>Journal of Clinical Oncology</i> , 2007, 25, 3952-3957.	1.6	42
31	JAK2-related pathway induces acquired erlotinib resistance in lung cancer cells harboring an epidermal growth factor receptor-activating mutation. <i>Cancer Science</i> , 2012, 103, 1795-1802.	3.9	40
32	Congestive Heart Failure During Osimertinib Treatment for Epidermal Growth Factor Receptor (EGFR)-mutant Non-small Cell Lung Cancer (NSCLC). <i>Internal Medicine</i> , 2017, 56, 2195-2197.	0.7	38
33	Percutaneous Radiofrequency Ablation of Lung Cancer Presenting as Ground-Glass Opacity. <i>CardioVascular and Interventional Radiology</i> , 2015, 38, 409-415.	2.0	37
34	Summary of the Japanese Respiratory Society statement for the treatment of lung cancer with comorbid interstitial pneumonia. <i>Respiratory Investigation</i> , 2019, 57, 512-533.	1.8	36
35	Complexity in the treatment of pulmonary large cell neuroendocrine carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2005, 131, 147-151.	2.5	35
36	Lower gefitinib dose led to earlier resistance acquisition before emergence of T790M mutation in epidermal growth factor receptor-mutated lung cancer model. <i>Cancer Science</i> , 2013, 104, 1440-1446.	3.9	34

#	ARTICLE	IF	CITATIONS
37	MET or NRAS amplification is an acquired resistance mechanism to the third-generation EGFR inhibitor naquotinib. <i>Scientific Reports</i> , 2018, 8, 1955.	3.3	34
38	The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer differ based on PD-L1 expression. <i>European Journal of Cancer</i> , 2021, 149, 73-81.	2.8	34
39	Effect of AZD1480 in an epidermal growth factor receptor-driven lung cancer model. <i>Lung Cancer</i> , 2014, 83, 30-36.	2.0	30
40	A phase II study of cisplatin plus S-1 with concurrent thoracic radiotherapy for locally advanced non-small-cell lung cancer: The Okayama Lung Cancer Study Group Trial 0501. <i>Lung Cancer</i> , 2015, 87, 141-147.	2.0	30
41	VEGFR2 blockade augments the effects of tyrosine kinase inhibitors by inhibiting angiogenesis and oncogenic signaling in oncogene-driven non-small-cell lung cancers. <i>Cancer Science</i> , 2021, 112, 1853-1864.	3.9	29
42	Lamivudine and Glycyrrhizin for Treatment of Chemotherapy-Induced Hepatitis B Virus (HBV) Hepatitis in a Chronic HBV Carrier with Non-Hodgkin Lymphoma. <i>Leukemia and Lymphoma</i> , 2001, 41, 191-195.	1.3	28
43	Impact of physical size on gefitinib efficacy in patients with non-small cell lung cancer harboring EGFR mutations. <i>Lung Cancer</i> , 2013, 81, 435-439.	2.0	28
44	A retinoid X receptor partial agonist attenuates pulmonary emphysema and airway inflammation. <i>Respiratory Research</i> , 2019, 20, 2.	3.6	28
45	Influence of age on the efficacy of immune checkpoint inhibitors in advanced cancers: a systematic review and meta-analysis. <i>Acta Oncologica</i> , 2020, 59, 249-256.	1.8	28
46	Clinical significance of repeat rebiopsy in detecting the EGFR T790M secondary mutation in patients with non-small cell lung cancer. <i>Oncotarget</i> , 2018, 9, 29525-29531.	1.8	28
47	Induction of lung adenocarcinoma in transgenic mice expressing activated <i>EGFR</i> driven by the SP1 promoter. <i>Cancer Science</i> , 2008, 99, 1747-1753.	3.9	27
48	Study Protocol: Phase-Ib Trial of Nivolumab Combined With Metformin for Refractory/Recurrent Solid Tumors. <i>Clinical Lung Cancer</i> , 2018, 19, e861-e864.	2.6	27
49	Short-term low-volume hydration in cisplatin-based chemotherapy for patients with lung cancer: the second prospective feasibility study in the Okayama Lung Cancer Study Group Trial 1201. <i>International Journal of Clinical Oncology</i> , 2016, 21, 81-87.	2.2	26
50	Phase 3 study of ceritinib vs chemotherapy in ALK-rearranged NSCLC patients previously treated with chemotherapy and crizotinib (ASCEND-5): Japanese subset. <i>Japanese Journal of Clinical Oncology</i> , 2018, 48, 367-375.	1.3	26
51	Characteristics of patients with EGFR-mutant non-small-cell lung cancer who benefited from immune checkpoint inhibitors. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 101-106.	4.2	26
52	A phase I trial of afatinib and bevacizumab in chemo-naïve patients with advanced non-small-cell lung cancer harboring EGFR mutations: Okayama Lung Cancer Study Group Trial 1404. <i>Lung Cancer</i> , 2018, 115, 103-108.	2.0	25
53	Therapeutic Potential of Afatinib for Cancers with <i>ERBB2</i> (<i>HER2</i>) Transmembrane Domain Mutations G660D and V659E. <i>Oncologist</i> , 2018, 23, 150-154.	3.7	25
54	Rapid and Long-term Response of Pulmonary Pleomorphic Carcinoma to Nivolumab. <i>Internal Medicine</i> , 2019, 58, 985-989.	0.7	25

#	ARTICLE	IF	CITATIONS
55	A Prospective Cohort Study to Define the Clinical Features and Outcome of Lung Cancers Harboring HER2 Aberration in Japan (HER2-CS STUDY). <i>Chest</i> , 2019, 156, 357-366.	0.8	25
56	Chemopreventive Effects of Gefitinib on Nonsmoking-Related Lung Tumorigenesis in Activating Epidermal Growth Factor Receptor Transgenic Mice. <i>Cancer Research</i> , 2009, 69, 7088-7095.	0.9	23
57	Osimertinib for Japanese patients with T790Mâ€positive advanced nonâ€smallâ€cell lung cancer: A pooled subgroup analysis. <i>Cancer Science</i> , 2019, 110, 2884-2893.	3.9	22
58	Rapid Acquisition of Alectinib Resistance in ALK-Positive Lung Cancer With High Tumor Mutation Burden. <i>Journal of Thoracic Oncology</i> , 2019, 14, 2009-2018.	1.1	22
59	A Japanese lung cancer registry study on demographics and treatment modalities in medically treated patients. <i>Cancer Science</i> , 2020, 111, 1685-1691.	3.9	22
60	Severe asthma concomitant with allergic bronchopulmonary aspergillosis successfully treated with mepolizumab. <i>Allergology International</i> , 2018, 67, 521-523.	3.3	21
61	Requirement for neuropeptide Y in the development of type 2 responses and allergen-induced airway hyperresponsiveness and inflammation. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2019, 316, L407-L417.	2.9	21
62	Mutation of the epidermal growth factor receptor gene in the development of adenocarcinoma of the lung. <i>Lung Cancer</i> , 2007, 58, 30-35.	2.0	20
63	Comprehensive analysis of EGFR signaling pathways in Japanese patients with non-small cell lung cancer. <i>Lung Cancer</i> , 2009, 66, 107-113.	2.0	20
64	Combined effect of cabozantinib and gefitinib in crizotinibâ€resistant lung tumors harboring ROS1 fusions. <i>Cancer Science</i> , 2018, 109, 3149-3158.	3.9	20
65	Utility of immune checkpoint inhibitors in nonâ€smallâ€cell lung cancer patients with poor performance status. <i>Cancer Science</i> , 2020, 111, 3739-3746.	3.9	20
66	STAT3 expression in activating EGFR-driven adenocarcinoma of the lung. <i>Lung Cancer</i> , 2012, 75, 24-29.	2.0	19
67	Trastuzumab Emtansine in HER2+ Recurrent Metastatic Nonâ€Small-Cell Lung Cancer: Study Protocol. <i>Clinical Lung Cancer</i> , 2017, 18, 92-95.	2.6	19
68	Cause of pleuroparenchymal fibroelastosis following allogeneic hematopoietic stem cell transplantation. <i>Respiratory Investigation</i> , 2019, 57, 321-324.	1.8	19
69	Phase 2 Study of Afatinib Alone or Combined With Bevacizumab in Chemo-naïve Patients With Advanced Nonâ€Small-Cell Lung Cancer Harboring EGFR Mutations: AfaBev-CS Study Protocol. <i>Clinical Lung Cancer</i> , 2019, 20, 134-138.	2.6	19
70	A phase II study of S-1 chemotherapy with concurrent thoracic radiotherapy in elderly patients with locally advanced non-small-cell lung cancer: The Okayama Lung Cancer Study Group Trial 0801. <i>European Journal of Cancer</i> , 2014, 50, 2783-2790.	2.8	18
71	Lower lobe origin is a poor prognostic factor in locally advanced non-small-cell lung cancer patients treated with induction chemoradiotherapy. <i>Molecular and Clinical Oncology</i> , 2015, 3, 706-712.	1.0	18
72	Endobronchial ultrasound-guided transbronchial biopsy with or without a guide sheath for diagnosis of lung Cancer. <i>Respiratory Investigation</i> , 2015, 53, 93-97.	1.8	18

#	ARTICLE	IF	CITATIONS
73	A phase II trial of EGFR-TKI readministration with afatinib in advanced non-small-cell lung cancer harboring a sensitive non-T790M EGFR mutation: Okayama Lung Cancer Study Group trial 1403. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 82, 1031-1038.	2.3	18
74	A phase III randomized trial comparing vindesine and cisplatin with or without ifosfamide in patients with advanced non-small-cell lung cancer: long-term follow-up results and analysis of prognostic factors. <i>Lung Cancer</i> , 2002, 36, 313-319.	2.0	17
75	Correlation of plasma crizotinib trough concentration with adverse events in patients with anaplastic lymphoma kinase positive non-small-cell lung cancer. <i>Journal of Pharmaceutical Health Care and Sciences</i> , 2015, 1, 8.	1.0	17
76	Safety and discomfort during bronchoscopy performed under sedation with fentanyl and midazolam: a prospective study. <i>Japanese Journal of Clinical Oncology</i> , 2016, 46, 871-874.	1.3	17
77	Chemoradiotherapy for locally advanced lung cancer patients with interstitial lung abnormalities. <i>Japanese Journal of Clinical Oncology</i> , 2019, 49, 458-464.	1.3	17
78	The effect of nivolumab treatment for central nervous system metastases in non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, e20601-e20601.	1.6	17
79	Magnitude of the Benefit of Progression-Free Survival as a Potential Surrogate Marker in Phase 3 Trials Assessing Targeted Agents in Molecularly Selected Patients with Advanced Non-Small Cell Lung Cancer: Systematic Review. <i>PLoS ONE</i> , 2015, 10, e0121211.	2.5	16
80	Phase I/II study of alectinib in lung cancer with <i>RET</i> fusion gene: study protocol. <i>Journal of Medical Investigation</i> , 2017, 64, 317-320.	0.5	16
81	Radiation pneumonitis after definitive concurrent chemoradiotherapy with cisplatin/docetaxel for non-small cell lung cancer: Analysis of dose-volume parameters. <i>Cancer Medicine</i> , 2020, 9, 4540-4549.	2.8	16
82	Potential influence of interleukin-6 on the therapeutic effect of gefitinib in patients with advanced non-small cell lung cancer harbouring EGFR mutations. <i>Biochemical and Biophysical Research Communications</i> , 2018, 495, 360-367.	2.1	15
83	Clinical activity of ASP8273 in Asian patients with non-small cell lung cancer with EGFR activating and T790M mutations. <i>Cancer Science</i> , 2018, 109, 2852-2862.	3.9	15
84	Re-administration of osimertinib in osimertinib-acquired resistant non-small-cell lung cancer. <i>Lung Cancer</i> , 2019, 132, 54-58.	2.0	15
85	Downregulation of TBXAS 1 in an iron-induced malignant mesothelioma model. <i>Cancer Science</i> , 2015, 106, 1296-1302.	3.9	14
86	Development of a skin rash within the first week and the therapeutic effect in afatinib monotherapy for EGFR-mutant non-small cell lung cancer (NSCLC): Okayama Lung Cancer Study Group experience. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 77, 1005-1009.	2.3	14
87	Ceritinib in patients with advanced, crizotinib-treated, anaplastic lymphoma kinase-rearranged NSCLC: Japanese subset. <i>Japanese Journal of Clinical Oncology</i> , 2017, 47, 618-624.	1.3	14
88	Triplet therapy with afatinib, cetuximab, and bevacizumab induces deep remission in lung cancer cells harboring EGFR T790M. <i>Molecular Oncology</i> , 2017, 11, 670-681.	4.6	14
89	Managing Lung Cancer with Comorbid Interstitial Pneumonia. <i>Internal Medicine</i> , 2020, 59, 163-167.	0.7	14
90	Immune checkpoint inhibitor efficacy and safety in older non-small cell lung cancer patients. <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 1447-1453.	1.3	14

#	ARTICLE	IF	CITATIONS
91	Sarcopenia is associated with poor prognosis after chemoradiotherapy in patients with stage III non-small-cell lung cancer: a retrospective analysis. <i>Scientific Reports</i> , 2021, 11, 11882.	3.3	14
92	Essential role of IL-23 in the development of acute exacerbation of pulmonary fibrosis. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2021, 321, L925-L940.	2.9	14
93	A phase I/II study with a highly selective ALK inhibitor CH5424802 in ALK-positive non-small cell lung cancer (NSCLC) patients: Updated safety and efficacy results from AF-001JP.. <i>Journal of Clinical Oncology</i> , 2013, 31, 8033-8033.	1.6	14
94	Gefitinib Combined With Standard Chemoradiotherapy in EGFR-Mutant Locally Advanced Non-Small-Cell Lung Cancer: The LOGIK0902/OLCSG0905 Intergroup Study Protocol. <i>Clinical Lung Cancer</i> , 2016, 17, 75-79.	2.6	13
95	Long-term effects of beta-blocker use on lung function in Japanese patients with chronic obstructive pulmonary disease. <i>International Journal of COPD</i> , 2017, Volume 12, 1119-1124.	2.3	13
96	Randomized, Double-Blind Phase Ib/III Study of Erlotinib With Ramucirumab or Placebo in Previously Untreated EGFR-Mutant Metastatic Non-Small-Cell Lung Cancer (RELAY): Phase Ib Results. <i>Clinical Lung Cancer</i> , 2018, 19, 213-220.e4.	2.6	13
97	Efficacy of afatinib treatment for lung adenocarcinoma harboring exon 18 delE709_T710insD mutation. <i>Japanese Journal of Clinical Oncology</i> , 2019, 49, 786-788.	1.3	13
98	Rapid on-site evaluation with BIOEVALUATOR® during endobronchial ultrasound-guided transbronchial needle aspiration for diagnosing pulmonary and mediastinal diseases. <i>Annals of Thoracic Medicine</i> , 2014, 9, 14.	1.8	12
99	Reappraisal of short-term low-volume hydration in cisplatin-based chemotherapy; hoping for it as a public domain. <i>Japanese Journal of Clinical Oncology</i> , 2015, 45, 603-4.	1.3	12
100	Dose-volume parameters predict radiation pneumonitis after induction chemoradiotherapy followed by surgery for non-small cell lung cancer: a retrospective analysis. <i>BMC Cancer</i> , 2019, 19, 1144.	2.6	12
101	Pilot evaluation of a HER2 testing in non-small-cell lung cancer. <i>Journal of Clinical Pathology</i> , 2020, 73, 353-357.	2.0	12
102	A New Human Lung Adenocarcinoma Cell Line Harboring the EML4-ALK Fusion Gene. <i>Japanese Journal of Clinical Oncology</i> , 2014, 44, 963-968.	1.3	11
103	Impact of body surface area on survival in EGFR-mutant non-small cell lung cancer patients treated with gefitinib monotherapy: observational study of the Okayama Lung Cancer Study Group 0703. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 251-256.	2.3	11
104	Nivolumab for the treatment of unresectable pleural mesothelioma. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 109-114.	3.1	11
105	Programmed cell death protein 1 and programmed death-ligand 1 are expressed on the surface of some small-cell lung cancer lines. <i>American Journal of Cancer Research</i> , 2015, 5, 1553-7.	1.4	11
106	Protocol Design for the Bench to Bed Trial in Alectinib-Refractory Non-Small-Cell Lung Cancer Patients Harboring the EML4-ALK Fusion Gene (ALRIGHT/OLCSG1405). <i>Clinical Lung Cancer</i> , 2016, 17, 602-605.	2.6	10
107	Clinical characteristics of Japanese candidates for lung transplant for interstitial lung disease and risk factors for early death while on the waiting list. <i>Respiratory Investigation</i> , 2017, 55, 264-269.	1.8	10
108	Osimertinib in patients with epidermal growth factor receptor T790M advanced non-small cell lung cancer selected using cytology samples. <i>Cancer Science</i> , 2018, 109, 1177-1184.	3.9	10

#	ARTICLE	IF	CITATIONS
109	<sc>ASP</sc>8273 tolerability and antitumor activity in tyrosine kinase inhibitor-naïve Japanese patients with EGFR mutation-positive non-small cell lung cancer. <i>Cancer Science</i> , 2018, 109, 2532-2538.	3.9	10
110	Lung transplant candidates with idiopathic pulmonary fibrosis and long-term pirfenidone therapy: Treatment feasibility influences waitlist survival. <i>Respiratory Investigation</i> , 2019, 57, 165-171.	1.8	10
111	Beneficial effect of erlotinib and trastuzumab emtansine combination in lung tumors harboring EGFR mutations. <i>Biochemical and Biophysical Research Communications</i> , 2020, 532, 341-346.	2.1	10
112	Lung stereotactic body radiation therapy for elderly patients aged ≥80 years with pathologically proven early-stage non-small cell lung cancer: a retrospective cohort study. <i>Radiation Oncology</i> , 2021, 16, 39.	2.7	10
113	CD8+ T-cell Responses Are Boosted by Dual PD-1/VEGFR2 Blockade after EGFR Inhibition in EGFR-Mutant Lung Cancer. <i>Cancer Immunology Research</i> , 2022, 10, 1111-1126.	3.4	10
114	Association of the benefit from gefitinib monotherapy with smoking status in Japanese patients with non-small-cell lung cancer. <i>Lung Cancer</i> , 2008, 62, 236-241.	2.0	9
115	Effect of gefitinib on N-nitrosamine-4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone induced lung tumorigenesis in A/J mice. <i>Lung Cancer</i> , 2009, 65, 284-289.	2.0	9
116	TAE226, a Bis-Anilino Pyrimidine Compound, Inhibits the EGFR-Mutant Kinase Including T790M Mutant to Show Anti-Tumor Effect on EGFR-Mutant Non-Small Cell Lung Cancer Cells. <i>PLoS ONE</i> , 2015, 10, e0129838.	2.5	9
117	Synergistic effect of pacritinib with erlotinib on JAK2-mediated resistance in epidermal growth factor receptor mutation-positive non-small cell lung Cancer. <i>Experimental Cell Research</i> , 2016, 344, 194-200.	2.6	9
118	Phase II Study of the EGFR-TKI Rechallenge With Afatinib in Patients With Advanced NSCLC Harboring Sensitive EGFR Mutation Without T790M: Okayama Lung Cancer Study Group Trial OLCSG 1403. <i>Clinical Lung Cancer</i> , 2017, 18, 241-244.	2.6	9
119	Long-term spontaneous remission with active surveillance in IgG4-related pleuritis: A case report and literature review. <i>Respiratory Medicine Case Reports</i> , 2019, 28, 100938.	0.4	9
120	Primary Resistance to Alectinib Was Lost after Bevacizumab Combined Chemotherapy in ALK-Rearranged Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2019, 14, e168-e169.	1.1	9
121	Successful Re-administration of Osimertinib in Osimertinib-induced Interstitial Lung Disease with an Organizing Pneumonia Pattern: A Case Report and Literature Review. <i>Internal Medicine</i> , 2020, 59, 823-828.	0.7	9
122	Impact of HER2 expression on EGFR-TKI treatment outcomes in lung tumors harboring EGFR mutations: A HER2-CS study subset analysis. <i>Lung Cancer</i> , 2020, 150, 83-89.	2.0	9
123	Association between poor performance status and risk for toxicity during erlotinib monotherapy in Japanese patients with non-small cell lung cancer: Okayama Lung Cancer Study Group experience. <i>Lung Cancer</i> , 2010, 70, 308-312.	2.0	8
124	Three-Arm Randomized Trial of Sodium Alginate for Preventing Radiation-Induced Esophagitis in Locally Advanced Non-Small Cell Lung Cancer Receiving Concurrent Chemoradiotherapy: The OLCSG1401 Study Protocol. <i>Clinical Lung Cancer</i> , 2017, 18, 245-249.	2.6	8
125	Clinical outcome of patients with recurrent non-small cell lung cancer after trimodality therapy. <i>Surgery Today</i> , 2019, 49, 601-609.	1.5	8
126	Identification of targetable kinases in idiopathic pulmonary fibrosis. <i>Respiratory Research</i> , 2022, 23, 20.	3.6	8

#	ARTICLE	IF	CITATIONS
127	A phase II study of topotecan and cisplatin with sequential thoracic radiotherapy in elderly patients with small-cell lung cancer: Okayama Lung Cancer Study Group 0102. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 78, 769-774.	2.3	7
128	The Feasibility of Median Sternotomy With or Without Thoracotomy for Locally Advanced Non-Small Cell Lung Cancer Treated With Induction Chemoradiotherapy. <i>Annals of Thoracic Surgery</i> , 2016, 102, 985-992.	1.3	7
129	A Long-term Response to Nivolumab in a Case of PD-L1-negative Lung Adenocarcinoma with an EGFR Mutation and Surrounding PD-L1-positive Tumor-associated Macrophages. <i>Internal Medicine</i> , 2019, 58, 3033-3037.	0.7	7
130	EGFR-TKI acquired resistance in lung cancers harboring EGFR mutations in immunocompetent C57BL/6j mice. <i>Lung Cancer</i> , 2019, 136, 86-93.	2.0	7
131	Recent treatment strategy for advanced squamous cell carcinoma of the lung in Japan. <i>International Journal of Clinical Oncology</i> , 2019, 24, 461-467.	2.2	7
132	Key prognostic factors for EGFR-mutated non-adenocarcinoma lung cancer patients in the Japanese Joint Committee of Lung Cancer Registry Database. <i>Lung Cancer</i> , 2020, 146, 236-243.	2.0	7
133	Impact of previous thoracic radiation therapy on the efficacy of immune checkpoint inhibitors in advanced non-small-cell lung cancer. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 279-286.	1.3	7
134	Randomized study comparing mannitol with furosemide for the prevention of cisplatin-induced renal toxicity in non-small cell lung cancer: The OLCSCG1406 trial. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2021, 17, 101-108.	1.1	7
135	Loss of IL-33 enhances elastase-induced and cigarette smoke extract-induced emphysema in mice. <i>Respiratory Research</i> , 2021, 22, 150.	3.6	7
136	A case of dramatic reduction in cancer-associated thrombus following initiation of pembrolizumab in patient with a poor performance status and PD-L1+ lung adenocarcinoma harboring CCDC6-RET fusion gene and NF1/TP53 mutations. <i>Lung Cancer</i> , 2021, 156, 1-4.	2.0	7
137	SHP2 Inhibition Enhances the Effects of Tyrosine Kinase Inhibitors in Preclinical Models of Treatment-naïve ALK-, ROS1-, or EGFR-altered Non-small Cell Lung Cancer. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 1653-1662.	4.1	7
138	Survival of chemo-naïve patients with EGFR mutation-positive advanced non-small cell lung cancer after treatment with afatinib and bevacizumab: updates from the Okayama Lung Cancer Study Group Trial 1404. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 1269-1276.	1.3	7
139	Pembrolizumab in advanced NSCLC patients with poor performance status and high PD-L1 expression: OLCSCG 1801. <i>International Journal of Clinical Oncology</i> , 2022, 27, 1139-1144.	2.2	7
140	Potential influence of being overweight on the development of hepatic dysfunction in Japanese patients with EGFR-mutated non-small cell lung cancer undergoing gefitinib monotherapy: the Okayama Lung Cancer Study Group experience. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 78, 941-947.	2.3	6
141	Discomfort during bronchoscopy performed after endobronchial intubation with fentanyl and midazolam: a prospective study. <i>Japanese Journal of Clinical Oncology</i> , 2017, 47, 434-437.	1.3	6
142	Osimertinib Depletes EGFR-T790M in the Spinal Fluid of Patients with Carcinomatous Meningitis of Lung Adenocarcinoma Harboring De Novo EGFR T790M. <i>Journal of Thoracic Oncology</i> , 2018, 13, e140-e142.	1.1	6
143	Survival and prognostic factors in elderly patients receiving second-line chemotherapy for relapsed small-cell lung cancer: Results from the Japanese Joint Committee of Lung Cancer Registry. <i>Lung Cancer</i> , 2020, 146, 160-164.	2.0	6
144	Pulmonary aspergillosis as a late complication after surgery for locally advanced non-small cell lung cancer treated with induction chemoradiotherapy. <i>Surgery Today</i> , 2020, 50, 863-871.	1.5	6

#	ARTICLE	IF	CITATIONS
145	Significance of PD-L1 expression in the cytological samples of non-small cell lung cancer patients treated with immune checkpoint inhibitors. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 3749-3755.	2.5	6
146	A novel osimertinib-resistant human lung adenocarcinoma cell line harbouring mutant <i>EGFR</i> and activated IGF1R. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 956-965.	1.3	6
147	A phase I/II study with a CNS-penetrant, selective ALK inhibitor alectinib in <i>ALK</i> -rearranged non-small cell lung cancer (<i>ALK</i> + NSCLC) patients (pts): Updates on progression free survival (PFS) and safety results from AF-001JP.. <i>Journal of Clinical Oncology</i> , 2015, 33, 8061-8061.	1.6	6
148	An oral fluoropyrimidine agent S-1 induced interstitial lung disease: A case report. <i>World Journal of Clinical Oncology</i> , 2011, 2, 299.	2.3	6
149	Short-term safety of an anti-severe acute respiratory syndrome coronavirus 2 messenger RNA vaccine for patients with advanced lung cancer treated with anticancer drugs: A multicenter, prospective, observational study. <i>Thoracic Cancer</i> , 2022, 13, 453-459.	1.9	6
150	The Effect of Gefitinib on B-RAF Mutant Non-small Cell Lung Cancer and Transfectants. <i>Journal of Thoracic Oncology</i> , 2007, 2, 321-324.	1.1	5
151	Triple Combination Chemotherapy with Cisplatin, Docetaxel, and Irinotecan for Advanced Non-small Cell Lung Cancer: A Phase I/II Trial. <i>Journal of Thoracic Oncology</i> , 2007, 2, 44-50.	1.1	5
152	Being overweight influences the development of hepatic dysfunction in Japanese patients with non-small-cell lung cancer undergoing cytotoxic chemotherapy. <i>Lung Cancer</i> , 2007, 55, 343-348.	2.0	5
153	Fever after lung radiofrequency ablation: Prospective evaluation of its incidence and associated factors. <i>European Journal of Radiology</i> , 2015, 84, 2202-2209.	2.6	5
154	Advantage of Induction Chemoradiotherapy for Lung Cancer in Securing Cancer-Free Bronchial Margin. <i>Annals of Thoracic Surgery</i> , 2017, 104, 971-978.	1.3	5
155	A phase II trial of carboplatin plus S-1 for elderly patients with advanced non-small-cell lung cancer with wild-type epidermal growth factor receptor: The Okayama Lung Cancer Study Group Trial 1202. <i>Lung Cancer</i> , 2017, 112, 188-194.	2.0	5
156	Recent trends in the treatment of unresectable stage III non-small-cell lung cancer. <i>Respiratory Investigation</i> , 2019, 57, 330-336.	1.8	5
157	Significance of re-biopsy of histological tumor samples in advanced non-small-cell lung cancer in clinical practice. <i>International Journal of Clinical Oncology</i> , 2019, 24, 41-45.	2.2	5
158	Deterioration of high-resolution computed tomography findings predicts disease progression after initial decline in forced vital capacity in idiopathic pulmonary fibrosis patients treated with pirfenidone. <i>Respiratory Investigation</i> , 2020, 58, 185-189.	1.8	5
159	Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Untreated Metastatic EGFR-Mutated NSCLC: RELAY Japanese Subset. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100171.	1.1	5
160	Chemopreventive effects and anti-tumorigenic mechanisms of 2,6-dimethoxy-1,4-benzoquinone, a constituent of <i>Vitis coignetiae</i> Pulliat (crimson glory vine, known as yamabudo in Japan), toward 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)-induced lung tumorigenesis in A/J mice. <i>Food and Chemical Toxicology</i> , 2021, 154, 112319.	3.6	5
161	Crizotinib for recurring non-small cell lung cancer with EML4-ALK fusion genes previously treated with alectinib: A phase II trial. <i>Thoracic Cancer</i> , 2021, 12, 643-649.	1.9	5
162	A first-in-human phase I/II study of ALK inhibitor CH5424802 in patients with ALK-positive NSCLC.. <i>Journal of Clinical Oncology</i> , 2012, 30, 7602-7602.	1.6	5

#	ARTICLE	IF	CITATIONS
163	First and repeat rebiopsy for detecting EGFR T790M mutation in non-small-cell lung cancer: CS-Lung-003 prospective observational registry study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 1869-1877.	2.5	5
164	Cavitary pulmonary involvement of diffuse large B-cell lymphoma transformed from extra nodal marginal zone B-cell lymphoma MALT type. <i>Clinical Journal of Gastroenterology</i> , 2011, 4, 401-406.	0.8	4
165	A Survey of Japanese Thoracic Oncologists' Perception of Diagnostic and Treatment Strategies for EGFR Mutant or EML4-ALK Fusion Non-small Cell Lung Cancer. <i>Chest</i> , 2014, 146, e222-e225.	0.8	4
166	Efficacy of multimodal treatment for leptomeningeal metastases in a lung cancer harboring an EGFR mutation. <i>OncoTargets and Therapy</i> , 2016, 9, 1753.	2.0	4
167	Induction chemoradiotherapy using docetaxel and cisplatin with definitive-dose radiation followed by surgery for locally advanced non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2017, 9, 3076-3086.	1.4	4
168	Granulation Tissue-induced Pseudo-relapse During Nivolumab Treatment in Advanced Non-small Cell Lung Cancer. <i>In Vivo</i> , 2019, 33, 2113-2115.	1.3	4
169	Therapies after first-line afatinib in patients with EGFR ⁺ NSCLC in Japan: retrospective analysis of LUX-Lung 3. <i>Future Oncology</i> , 2020, 16, 49-60.	2.4	4
170	Secondary Pulmonary Alveolar Proteinosis Associated with Primary Myelofibrosis and Ruxolitinib Treatment: An Autopsy Case. <i>Internal Medicine</i> , 2020, 59, 2023-2028.	0.7	4
171	Demand for weekend outpatient chemotherapy among patients with cancer in Japan. <i>Supportive Care in Cancer</i> , 2021, 29, 1287-1291.	2.2	4
172	Sarcopenia is related to poor prognosis in patients after trimodality therapy for locally advanced non-small cell lung cancer. <i>International Journal of Clinical Oncology</i> , 2021, 26, 1450-1460.	2.2	4
173	Protective Effects of Bisoprolol against Acute Exacerbation in Moderate-to-Severe Chronic Obstructive Pulmonary Disease. <i>Acta Medica Okayama</i> , 2017, 71, 453-457.	0.2	4
174	Detection of epidermal growth factor receptor mutations in exhaled breath condensate using droplet digital polymerase chain reaction. <i>Oncology Letters</i> , 2020, 20, 1-1.	1.8	4
175	Cisplatin-induced hyponatremia in malignancy: comparison between brand-name and generic formulation. <i>Drug Design, Development and Therapy</i> , 2014, 8, 2401.	4.3	3
176	Current status and future perspectives of cooperative study groups for lung cancer in Japan. <i>Respiratory Investigation</i> , 2014, 52, 339-347.	1.8	3
177	Second primary cancer in survivors of locally advanced non-small cell lung cancer treated with concurrent chemoradiation followed by surgery. <i>Japanese Journal of Clinical Oncology</i> , 2018, 48, 287-290.	1.3	3
178	Needle wash solution cultures following EBUS-TBNA with or without endobronchial intubation. <i>Respiratory Investigation</i> , 2018, 56, 356-360.	1.8	3
179	Beneficial Effect of Osimertinib Readministration in Non-small-cell Lung Cancer Harboring an Epidermal Growth Factor Receptor (EGFR) Mutation with a History of Acquired Resistance to Osimertinib. <i>Internal Medicine</i> , 2019, 58, 1625-1627.	0.7	3
180	A phase I/II trial of weekly nab-paclitaxel for pretreated non-small-cell lung cancer patients without epidermal growth factor receptor mutations and anaplastic lymphoma kinase rearrangement. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2019, 15, 250-256.	1.1	3

#	ARTICLE	IF	CITATIONS
181	Chemoradiation therapy for non-small cell lung cancer exacerbates thoracic aortic calcification determined by computed tomography. <i>Heart and Vessels</i> , 2020, 35, 1401-1408.	1.2	3
182	A PET/CT volumetric parameter predicts prognosis of non-small cell lung cancer treated using preoperative chemoradiotherapy and surgery: A retrospective case series study. <i>Molecular and Clinical Oncology</i> , 2021, 14, 73.	1.0	3
183	Comparison of bronchoscopy and computed tomography-guided needle biopsy for re-biopsy in non-small cell lung cancer patients. <i>Respiratory Investigation</i> , 2021, 59, 240-246.	1.8	3
184	Interstitial Pneumonia Secondary to Hermansky-Pudlak Syndrome Type 4 Treated with Different Antifibrotic Agents. <i>Internal Medicine</i> , 2021, 60, 783-788.	0.7	3
185	A randomized phase III study of cisplatin (CDDP), etoposide (ETOP) and irinotecan versus topotecan as second-line chemotherapy in patients with sensitive relapsed small-cell lung cancer (SCLC): Japan Clinical Oncology Group study JCOG0605. <i>Journal of Clinical Oncology</i> , 2014, 32, 7504-7504.	1.6	3
186	Endobronchial ultrasound-guided transbronchial needle aspiration of hilar and mediastinal lymph nodes detected on ¹⁸ F-fluorodeoxyglucose positron emission tomography/computed tomography. <i>Japanese Journal of Clinical Oncology</i> , 2016, 46, 529-533.	1.3	2
187	Is Surgery after Chemoradiotherapy Feasible in Lung Cancer Patients with Superior Vena Cava Invasion?. <i>Annals of Thoracic and Cardiovascular Surgery</i> , 2018, 24, 131-138.	0.8	2
188	Programmed cell death-ligand 1 expression and efficacy of cisplatin-based chemotherapy in lung cancer: A sub-analysis of data from the two Okayama Lung Cancer Study Group prospective feasibility studies. <i>Respiratory Investigation</i> , 2019, 57, 460-465.	1.8	2
189	Patients' preferences and perceptions of lung cancer treatment decision making: results from Okayama lung cancer study group trial 1406. <i>Acta Oncologica</i> , 2020, 59, 324-328.	1.8	2
190	Novel prospective umbrella-type lung cancer registry study for clarifying clinical practice patterns: CS&Lung study protocol. <i>Thoracic Cancer</i> , 2021, 12, 725-731.	1.9	2
191	Dramatic Response to Carboplatin Plus Paclitaxel in Pancreatic Mucinous Cystadenocarcinoma with Liver Metastasis. <i>Internal Medicine</i> , 2021, 60, 2967-2971.	0.7	2
192	A phase II trial of induction gefitinib monotherapy followed by cisplatin-docetaxel and concurrent thoracic irradiation in patients with EGFR-mutant locally advanced non-small-cell lung cancer (LA-NSCLC): LOGIK0902/OLCSG0905 intergroup trial.. <i>Journal of Clinical Oncology</i> , 2012, 30, 7045-7045.	1.6	2
193	The effect and safety of an immune checkpoint inhibitor rechallenge in non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, e21147-e21147.	1.6	2
194	Anaplastic Lymphoma Kinase Fusion: A Review of Therapeutic Drugs and Treatment Strategies. <i>Acta Medica Okayama</i> , 2020, 74, 371-379.	0.2	2
195	Visceral Adipose Mass and Radiation Pneumonitis After Concurrent Chemoradiotherapy in Patients With Non-small-cell Lung Cancer. <i>Cancer Diagnosis & Prognosis</i> , 2021, 1, 61-67.	0.7	2
196	Targeting ROR1 in combination with osimertinib in EGFR mutant lung cancer cells. <i>Experimental Cell Research</i> , 2021, 409, 112940.	2.6	2
197	Rapid Disease Progression of Advanced Non-small Cell Lung Cancer Five Months after Cessation of Pembrolizumab. <i>Acta Medica Okayama</i> , 2020, 74, 423-425.	0.2	2
198	Efficacy of platinum agents for stage III non-small-cell lung cancer following platinum-based chemoradiotherapy: a retrospective study. <i>BMC Cancer</i> , 2022, 22, 342.	2.6	2

#	ARTICLE	IF	CITATIONS
199	Dasatinib-induced massive left chylothorax in a patient with chronic myeloid leukemia. <i>Respiratory Medicine Case Reports</i> , 2022, 37, 101662.	0.4	2
200	Three doses of mRNA COVID-19 vaccine protects from SARS-CoV-2 infections in Japan. <i>Journal of Internal Medicine</i> , 2022, 292, 687-689.	6.0	2
201	Afatinib (Afa) + bevacizumab (Bev) versus afatinib alone as first-line treatment of patients with EGFR-mutated advanced non-squamous NSCLC: Primary analysis of the multicenter, randomized, phase II study "AfaBev-CS study". <i>Journal of Clinical Oncology</i> , 2022, 40, 9112-9112.	1.6	2
202	Mixed Response to Cancer Immunotherapy is Driven by Intratumor Heterogeneity and Differential Interlesion Immune Infiltration. <i>Cancer Research Communications</i> , 2022, 2, 739-753.	1.7	2
203	Phase I/II Study of Alectinib (CH5424802/RO5424802) in Patients with ALK-rearranged Non-small Cell Lung Cancer (NSCLC): Updated Results from the AF-001JP Trial. <i>Japanese Journal of Lung Cancer</i> , 2014, 54, 892-897.	0.1	1
204	Chemotherapy for lung cancer: still alive!. <i>Japanese Journal of Clinical Oncology</i> , 2015, 45, 609-610.	1.3	1
205	A questionnaire survey of pharmacists regarding the clinical practice guidelines for the appropriate use of granulocyte-colony stimulating factors. <i>Journal of Pharmaceutical Health Care and Sciences</i> , 2018, 4, 2.	1.0	1
206	Pulmonary Aspergilloma and Allergic Bronchopulmonary Aspergillosis Following the 2018 Heavy Rain Event in Western Japan. <i>Internal Medicine</i> , 2022, 61, 379-383.	0.7	1
207	A case of interstitial pneumonia associated with systemic sclerosis and primary peritoneal serous carcinoma successfully treated with cyclophosphamide. <i>International Cancer Conference Journal</i> , 2021, 10, 197-200.	0.5	1
208	Triple therapy with osimertinib, bevacizumab and cetuximab in EGFR mutant lung cancer with HIF1 α /TGF α expression. <i>Oncology Letters</i> , 2021, 22, 639.	1.8	1
209	Impact of body surface area on efficacy of gefitinib in patients with non-small cell lung cancer harboring activating epidermal growth factor receptor mutation. <i>Journal of Clinical Oncology</i> , 2012, 30, 2607-2607.	1.6	1
210	Phase II study of topotecan and cisplatin with sequential radiotherapy in elderly small cell lung cancer patients (Okayama Lung Cancer Study Group; OLCSG 0102). <i>Journal of Clinical Oncology</i> , 2015, 33, 7572-7572.	1.6	1
211	Development of skin rash within the 1st week is a potential surrogate marker of therapeutic effect in afatinib monotherapy in patients with EGFR-mt non-small-cell lung cancer (NSCLC): Okayama Lung Cancer Study Group Experience. <i>Journal of Clinical Oncology</i> , 2015, 33, e19051-e19051.	1.6	1
212	Crizotinib to overcome alectinib-resistance in non-small cell lung cancer (NSCLC) harboring EML4-ALK. <i>Journal of Clinical Oncology</i> , 2015, 33, e19140-e19140.	1.6	1
213	Impact of HER2 aberrations on EGFR-TKI treatment outcomes in lung tumors harboring EGFR mutations: A HER2-CS STUDY subset analysis. <i>Journal of Clinical Oncology</i> , 2019, 37, 9056-9056.	1.6	1
214	Randomized phase II study comparing mannitol with furosemide for the prevention of cisplatin-induced renal toxicity in advanced non-small cell lung cancer: The OLCSG1406 trial. <i>Journal of Clinical Oncology</i> , 2019, 37, e23105-e23105.	1.6	1
215	A prospective cohort study to define the clinical and pathological features of lung cancers harboring HER2 gene aberrations (the HER2-CS Study) and a phase II study of trastuzumab emtansine (recombinant) in patients with HER2-positive non-small cell lung cancer who recurred, progressed after standard chemotherapy, or were primarily refractory to standard chemotherapy. <i>Okayama Igakkai Zasshi</i> , 2015, 127, 127-132.	0.0	1
216	Tolerability and antitumor activity of ASP8273 in TKI-naïve Japanese subjects with EGFR mutation-positive non-small cell lung cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 9037-9037.	1.6	1

#	ARTICLE	IF	CITATIONS
217	RELAY study of erlotinib (ERL) + ramucirumab (RAM) or placebo (PL) in EGFR-mutated metastatic non-small cell lung cancer (NSCLC): Biomarker analysis using circulating tumor DNA (ctDNA) in Japanese patients (pts).. Journal of Clinical Oncology, 2020, 38, 9527-9527.	1.6	1
218	Advanced Non-Small Cell Lung Carcinoma: Acquired Resistance to Gefitinib. , 2008, , 307-316.		1
219	Creation of an Integrated Clinical Trial Database and Data Sharing for Conducting New Research by the Japan Lung Cancer Society. JTO Clinical and Research Reports, 2022, 3, 100317.	1.1	1
220	Can dose-dense chemotherapy improve outcome in patients with better-prognosis small-cell lung cancer?. Nature Clinical Practice Oncology, 2005, 2, 610-611.	4.3	0
221	New treatment strategy for patients with EGFR-mutant lung cancer. Lung Cancer Management, 2013, 2, 505-516.	1.5	0
222	Pharmacokinetics of amrubicin in lung cancer patients with impaired hepatic function. Cancer Treatment and Research Communications, 2016, 9, 81-87.	1.7	0
223	A case of axillary lymphadenitis caused by Mycobacterium intracellulare in an immunocompetent patient. Respiratory Medicine Case Reports, 2019, 28, 100947.	0.4	0
224	A randomized trial of sodium alginate prevention of esophagitis in LA-NSCLC receiving chemoradiotherapy: OLCSG1401. Supportive Care in Cancer, 2021, 29, 5237-5244.	2.2	0
225	The 61st Annual Meeting of the Japan Lung Cancer Society: Eradication of lung cancer 2020. Okayama Igakkai Zasshi, 2021, 133, 80-82.	0.0	0
226	Impact on second-line treatment after failure of immune checkpoint inhibitor (ICI) combination chemotherapy in extensive-disease small cell lung cancer: Experience of the Okayama Lung Cancer Study Group.. Journal of Clinical Oncology, 2021, 39, e20590-e20590.	1.6	0
227	Response to letter re: The effects of antibiotics on the efficacy of immune-checkpoint inhibitors in non-small cell lung cancer patients differ according to PD-L1 expression. European Journal of Cancer, 2021, 157, 523-524.	2.8	0
228	llâ€€,°ç™Ēã®â†…çšćš,,æ²»ç™,. Okayama Igakkai Zasshi, 2008, 119, 285-292.	0.0	0
229	A randomized phase III study of a cisplatin (CDDP) and docetaxel (DOC) with or without irinotecan (CPT) in pts with advanced NSCLC: Okayama Lung Cancer Study Group OLCSG 0403 trial.. Journal of Clinical Oncology, 2012, 30, 7560-7560.	1.6	0
230	Survival post-progression (SPP) in phase III trials of chemotherapy in advanced NSCLC: Its potentially different impact on OS in the first-line and salvage settings.. Journal of Clinical Oncology, 2012, 30, e18027-e18027.	1.6	0
231	A phase II study of cisplatin (P), S-1 (S), and concurrent thoracic radiotherapy (TRT) for locally advanced non-small cell lung cancer (LA-NSCLC): Okayama Lung Cancer Study Group trial 0501.. Journal of Clinical Oncology, 2012, 30, 7042-7042.	1.6	0
232	Difference in incidence and pattern of salvage treatment after failure to first-line epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) monotherapy and standard cytotoxic chemotherapy in pts with advanced non-small cell lung cancer (NSCLC) harboring EGFR mutations: Okayama Lung Cancer Study Group experience.. Journal of Clinical Oncology, 2012, 30, 7576-7576.	1.6	0
233	Impact of body surface area (BSA) on efficacy of gefitinib in patients with non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2013, 31, e19167-e19167.	1.6	0
234	Survival analysis of induction cisplatin (CDDP)-docetaxel (DOC)-bevacizumab (BEV) chemotherapy followed by maintenance BEV-pemetrexed (PEM) therapy in advanced nonsquamous non-small cell lung cancer (NonSq NSCLC): A phase II trial from Okayama Lung Cancer Study Group 0903.. Journal of Clinical Oncology, 2013, 31, e19040-e19040.	1.6	0

#	ARTICLE	IF	CITATIONS
235	Prospective cohort study of serum sialylated glycoprotein (KL-6) as a prognostic marker in patients (pts) with non-small cell lung cancer (NSCLC) receiving gefitinib monotherapy: Okayama Lung Cancer Study Group 0703.. <i>Journal of Clinical Oncology</i> , 2013, 31, e19023-e19023.	1.6	0
236	A survey on Japanese thoracic oncologistsâ€™ preference on treatment strategy for EGFR-mutant or EML4-ALK-mutant non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2013, 31, e19124-e19124.	1.6	0
237	Factors affecting PS deterioration at the time of relapse after the first-line EGFR-TKI therapy in EGFR-mutant advanced NSCLC.. <i>Journal of Clinical Oncology</i> , 2014, 32, e19102-e19102.	1.6	0
238	Time trend in the survival advantage in phase III trials investigating molecular-targeted agents for advanced non-small cell lung cancer (NSCLC) during the past decade.. <i>Journal of Clinical Oncology</i> , 2014, 32, e19084-e19084.	1.6	0
239	A phase II study of S-1 and concurrent thoracic radiotherapy (TRT) for elderly pts with locally advanced non-small cell lung cancer (LA-NSCLC): Okayama Lung Cancer Study Group trial 0801.. <i>Journal of Clinical Oncology</i> , 2014, 32, 7576-7576.	1.6	0
240	Publication of Lung Cancer Clinical Trials in Japan. <i>Japanese Journal of Lung Cancer</i> , 2015, 55, 1070-1074.	0.1	0
241	Three-arm randomized trial of sodium alginate, orally administered mucoprotective agent, for preventing radiation esophagitis in pts with locally advanced non-small-cell lung cancer (LA-NSCLC) receiving concurrent chemoradiotherapy (CRT): Okayama Lung Cancer Study Group 1401.. <i>Journal of Clinical Oncology</i> , 2015, 33, TPS9641-TPS9641.	1.6	0
242	Second primary cancer in survivors of locally advanced NSCLC treated with concurrent chemoradiation followed by surgery.. <i>Journal of Clinical Oncology</i> , 2016, 34, 10100-10100.	1.6	0
243	Association with consolidation chemotherapy after concurrent chemoradiotherapy followed by surgery and the disease free survival in patients with stage III non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2016, 34, e20053-e20053.	1.6	0
244	A phase II trial of carboplatin plus S-1 for elderly patients with advanced non-small cell lung cancer with wild type EGFR (OLCSG1202).. <i>Journal of Clinical Oncology</i> , 2017, 35, e20614-e20614.	1.6	0
245	Chemoradiotherapy (CRT) for locally-advanced (LA) lung cancer patients with interstitial lung abnormalities (ILA).. <i>Journal of Clinical Oncology</i> , 2017, 35, e20057-e20057.	1.6	0
246	Phase Ib trial of nivolumab combined with metformin for refractory/recurrent solid tumors.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS3119-TPS3119.	1.6	0
247	Immune checkpoint inhibitor efficacy and safety in elderly non-small cell lung cancer patients.. <i>Journal of Clinical Oncology</i> , 2018, 36, e21034-e21034.	1.6	0
248	Treatment for Advanced Squamous Cell Carcinoma of the Lung. <i>Japanese Journal of Lung Cancer</i> , 2018, 58, 325-330.	0.1	0
249	Tumor microenvironment affecting the effect of immuno-checkpoint inhibitors. <i>Okayama Igakkai Zasshi</i> , 2019, 131, 51-53.	0.0	0
250	Transformed diffuse large B-cell lymphoma from marginal zone lymphoma in the anterior mediastinum: A case report and review of the literature. <i>Journal of Clinical and Experimental Hematopathology: JCEH</i> , 2021, 62, .	0.8	0
251	Protective effects of neuropeptide Y against elastase-induced pulmonary emphysema. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2022, , .	2.9	0
252	Volumetric PET Parameters Predict Prognosis after Definitive Chemoradiotherapy with Cisplatin/Docetaxel for Stage III Non-Small Cell Lung Cancer. <i>Acta Medica Okayama</i> , 2021, 75, 15-23.	0.2	0

#	ARTICLE	IF	CITATIONS
253	Clinical Outcome of Palliative Concurrent Chemoradiotherapy with Cisplatin/Docetaxel for Stage III Non-small Cell Lung Cancer. <i>Acta Medica Okayama</i> , 2021, 75, 269-277.	0.2	0
254	Preventive effect of goshajinkigan against peripheral neuropathy induced by paclitaxel-containing chemotherapy: An open-label, randomized, phase II study.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS12141-TPS12141.	1.6	0